{"id":9697,"date":"2011-01-21T00:00:00","date_gmt":"2011-01-20T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2011\/01\/21\/lidibell-lidera-un-projecte-europeu-per-desenvolupar-terapies-personalitzades-en-cancer-de-pulmo\/"},"modified":"2020-05-13T19:50:56","modified_gmt":"2020-05-13T17:50:56","slug":"lidibell-lidera-un-projecte-europeu-per-desenvolupar-terapies-personalitzades-en-cancer-de-pulmo","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2011\/01\/lidibell-lidera-un-projecte-europeu-per-desenvolupar-terapies-personalitzades-en-cancer-de-pulmo\/","title":{"rendered":"L\u2019IDIBELL lidera un projecte europeu per desenvolupar ter\u00e0pies personalitzades en c\u00e0ncer de pulm\u00f3"},"content":{"rendered":"

L\u2019objectiu final del projecte CURELUNG \u00e9s descobrir alteracions gen\u00e8tiques en el c\u00e0ncer de pulm\u00f3 i investigar f\u00e0rmacs que actu\u00efn espec\u00edficament sobre les c\u00e8l\u00b7lules tumorals. D\u2019aquesta manera cada pacient podria rebre un tractament espec\u00edfic i eficient. <\/p>\n

<\/object> <\/p>\n

El 20 de gener s\u2019ha donat el tret de sortida el projecte Curelung, promogut per la Uni\u00f3 Europea dins el 7\u00e8 Programa Marc de Recerca i Desenvolupament. En total, onze institucions de set pa\u00efsos europeus en formen part. Ha estat en una jornada de presentaci\u00f3 celebrada a la sala d\u2019actes de l\u2019Hospital Duran i Reynals (ICO) en la qual els participants han marcat les l\u00ednies que se seguiren en el programa, que compta amb un finan\u00e7ament de 3,8 milions d\u2019euros, durant els propers tres anys. <\/p>\n

L\u2019investigador de l\u2019IDIBELL i coordinador del projecte, Manel Esteller, ha explicat que el prop\u00f2sit de la investigaci\u00f3 \u00e9s analitzar el genoma de les c\u00e8l\u00b7lules tumorals a la recerca de marcadors que responguin a f\u00e0rmacs ja existents, de manera que \u201cobtindrem un perfil dels tumors de pulm\u00f3 humans que ens permetria predir quins pacients tindran una millor resposta a un determinat f\u00e0rmac. La idea \u00e9s arribar al tractament de c\u00e0ncer de pulm\u00f3 personalitzat. El millor f\u00e0rmac per al millor pacient\u201d. <\/p>\n

Ter\u00e0pies dirigides<\/strong> <\/p>\n

En l\u2019\u00faltima d\u00e8cada s\u2019han fet aven\u00e7os en la creaci\u00f3 de ter\u00e0pies dirigides contra prote\u00efnes oncog\u00e8niques que han perm\u00e8s crear f\u00e0rmacs per tractar tumors al pulm\u00f3 , per\u00f2 \u201cel percentatge de pacients que presenten aquestes alteracions \u00e9s molt baix\u201d.Per aix\u00f2 en el projecte participen investigadors l\u00edders en la recerca del c\u00e0ncer de pulm\u00f3 des de diverses perspectives. Compten amb tecnologia d\u2019\u00faltima generaci\u00f3 en an\u00e0lisis massiu de gen\u00f2mica i transcript\u00f2mica per identificar nous gens i determinar biomarcadors, <\/p>\n

aix\u00ed com amb diversos models experimentals i amb col\u00b7leccions de mostres de c\u00e0ncer de pulm\u00f3 hum\u00e0. <\/p>\n

Manel Esteller ha assegurat que es donaria per satisfet si despr\u00e9s de tres anys d\u2019investigaci\u00f3 s\u2019aconsegueix identificar \u201cun marcador que respongui a un f\u00e0rmac determinat i atreure aix\u00ed a les autoritats competents per iniciar una fase d\u2019assaig cl\u00ednic\u201d per aconseguir una ter\u00e0pia personalitzada contra el c\u00e0ncer de pulm\u00f3. <\/p>\n

El c\u00e0ncer m\u00e9s letal <\/strong> <\/p>\n

El c\u00e0ncer de pulm\u00f3 \u00e9s actualment el c\u00e0ncer m\u00e9s letal del m\u00f3n. A Europa se\u2019n diagnostiquen cada any m\u00e9s de 150.000 casos, un 90% d\u2019ells a causa del tabac. Nom\u00e9s entre un 10 i un 15% sobreviuen cinc anys despr\u00e9s de la diagnosi. Aix\u00f2 es deu \u201cen part a que el 80% dels casos el c\u00e0ncer de pulm\u00f3 es diagnostica en un estat tan avan\u00e7at que ja no \u00e9s possible operar i en part perqu\u00e8 els pacients responen relativament malament a les ter\u00e0pies habituals\u201d ha explicat l\u2019investigadora de l\u2019IDIBELL, Montse S\u00e1nchez-C\u00e9spedes.<\/p>\n

En aquest sentit, \u201cun altre dels objectius del projecte Curelung \u00e9s estudiar els mecanismes de resist\u00e8ncia de les c\u00e8l\u00b7lules tumorals als f\u00e0rmacs\u201d. <\/p>\n

Els investigadors del projecte Curelung<\/strong> <\/p>\n

\".\" Manel Esteller, IDIBELL <\/p>\n

\".\" Montse S\u00e1nchez-C\u00e9spedes, IDIBELL<\/p>\n

John K. Field, University of Liverpool (UK) <\/p>\n

\".\" Elisabeth Bambrilla, University Joseph Fourier (France) <\/p>\n

\".\" Luis Montuenga, FIMA (Spain) <\/p>\n

\".\" Roman Thomas, Max Plank Institut (Germany) <\/p>\n

\".\" Luca Roz, INT (Italy)<\/p>\n

\".\" Giorgio Scagliotti , University of Torino (Italy) <\/p>\n

\".\" Benjamin Besse, Institut Gustave Roussy (France) <\/p>\n

\".\" J\u00fcrgen Wolf, Clinic University of Kl\u00f6n (Germany) <\/p>\n

\".\" Krzysztof Kucharczyk, Biovectis (Poland) <\/p>\n

\".\" Suvi Saviola, MRCH (Netehrlands)<\/p>\n","protected":false},"excerpt":{"rendered":"

Ter\u00e0pies dirigides El c\u00e0ncer m\u00e9s letal Els investigadors del projecte Curelung<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9697","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-12-26 06:42:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9697"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9697\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}